AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE1035.30-7.65 (-0.73 %)
PREV CLOSE ( ) 1042.95
OPEN PRICE ( ) 1033.00
BID PRICE (QTY) 1035.30 (290)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 41137
TODAY'S LOW / HIGH ( )1005.00 1044.95
52 WK LOW / HIGH ( )897.6 1592
NSE1038.30-4.4 (-0.42 %)
PREV CLOSE( ) 1042.70
OPEN PRICE ( ) 1041.70
BID PRICE (QTY) 1038.30 (109)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 772286
TODAY'S LOW / HIGH( ) 1004.60 1046.60
52 WK LOW / HIGH ( )895.85 1599
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 31-12 1979
Management Info
Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director
Registered Office

Address Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone 91-22-66061000

Email info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS
08Jun Notice Of 39Th Annual General Meeting
Please find enclosed the Notice of the 39th AGM and the Annual Report fo..
11May Announcement under Regulation 30 (LOD
This is to inform that the Compensation Committee of the Board has at it..
03May Date Of Closure Of Transfer Books
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosur..
03May Ajanta Pharma informs about company up
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosur..
20Apr Board Meeting On Wednesday, 2Nd May,
Pursuant to Regulation 29 of the Listing Regulations, we hereby inform t..
Financials
Rs. in Millions
QTR Mar 18 ANNUAL 18
Net Profit7854275.2
Gross Profit 1054.4 5624.4
Operating Profit 1214.16198.2
Net Sales 462618304.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 7430.85 (1.82%)
M.Cap (Rs. in Cr)15790.04
Astrazeneca Pharma I (BSE)
 1478.55 (9.32%)
M.Cap (Rs. in Cr)3696.38
Piramal Enterprises (BSE)
 2602.35 (2.48%)
M.Cap (Rs. in Cr)46996.49
Sun Pharma Inds. (BSE)
 576.30 (3.91%)
M.Cap (Rs. in Cr)138273.07
Glaxosmithkline Phar (BSE)
 2801.00 (0.70%)
M.Cap (Rs. in Cr)23725.32
Shareholding Pattern
PROMOTERS 70.7%
NON-INSTITUTION 10.32%
MUTUAL FUNDS/UTI 6.14%
GOVERNMENT 0.27%
FI/BANKS/INSURANCE 0.25%
FII 0%
ATTENTION INVESTORSKYCIPO
REGISTRATION NOS.

NSE CM-INB231215030|NSE F& O - INF231215030, NSE CD-INE231215030, BSE CM–INB011215036 |BSE F & O - INF011215036 MCX-SX CM-INB261215033|MCX-SX F & O - INF261215033|MCX-SX CD-INE261215033 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912

INVESTOR PROTECTION

Compliance officer : Aishwarya M. Kalal, Tel no: 022-40790032, Mobile no- 9773104340, E-mail id- Complaince@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Copyright © 2016 NNM Securities.com

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.